SCHEMBL1809601

SCHEMBL1809601

O=C(CCl)NCC1CN(Cc2ccc(F)c(F)c2)CCO1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD4 P21917 12/20 0.54
MCHR1 Q99705 1/20 0.53
CCR3 P51677 1/20 0.52
SIGMAR1 Q99720 6/20 0.48
MEN1 O00255 1/20 0.48
LMNA P02545 1/20 0.48
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
HTR1A P08908 1/20 0.48
ADRA2A P08913 1/20 0.48
ADORA3 P0DMS8 1/20 0.48
CYP2C9 P11712 1/20 0.48
ADRA2B P18089 1/20 0.48
HTR2C P28335 1/20 0.48
SLC6A4 P31645 1/20 0.48
CYP2C19 P33261 1/20 0.48
DRD3 P35462 1/20 0.48
HTR2B P41595 1/20 0.48
KMT2A Q03164 1/20 0.48
KCNH2 Q12809 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1809602 1.00 DRD4 (0.54) DRD4MCHR1CCR3SIGMAR1MEN1
SCHEMBL1807499 0.93 DRD4 (0.57) DRD4MCHR1CCR3SIGMAR1MEN1
SCHEMBL1807501 0.93 DRD4 (0.57) DRD4MCHR1CCR3SIGMAR1MEN1
Hydrochloric Acid SCHEMBL1809651 0.92 DRD4 (0.56) DRD4MCHR1CCR3SIGMAR1MEN1
Hydrochloric Acid SCHEMBL1809649 0.92 DRD4 (0.56) DRD4MCHR1CCR3SIGMAR1MEN1
SCHEMBL4021624 0.87 CCR3 (0.59) DRD4MCHR1CCR3SIGMAR1MEN1
SCHEMBL1808369 0.87 CCR3 (0.66) DRD4CCR3SIGMAR1MEN1LMNA
SCHEMBL1808367 0.87 CCR3 (0.66) DRD4CCR3SIGMAR1MEN1LMNA
SCHEMBL4226628 0.87 CCR3 (0.66) DRD4CCR3SIGMAR1MEN1LMNA
SCHEMBL30211808 0.87 DRD4 (0.56) DRD4MCHR1CCR3SIGMAR1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1801108-B9 MORPHOLINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATIONS MITSUBISHI TANABE PHARMA CORP (JP) 2013-11-20 EP disclosed
EP-1801108-B1 MORPHOLINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATIONS MITSUBISHI TANABE PHARMA CORP (JP) 2012-11-14 EP disclosed
US-7935700-B2 Morpholine compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-05-03 US disclosed
US-20070265257-A1 Morpholine Compound MITSUBISHI PHARMA CORPORATION (JP) 2007-11-15 US disclosed
EP-1801108-A1 MORPHOLINE COMPOUND Mitsubishi Pharma Corporation (JP) 2007-06-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070265257-A1 Morpholine Compound CCR3, CCR1, CCR4 DRD4 768/4885MCHR1 301/4885CCR3 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.